![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Pneumonitis
January 26, 2022
This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
September 14, 2020
This phase II trial by EA's Cancer Control and Survivorship Committee is comparing two promising pneumonitis treatments for patients receiving PD-1/PD-L1 therapy